2023
DOI: 10.3390/kinasesphosphatases1010006
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic Perspectives on ROCK Inhibition for Cerebral Cavernous Malformations

Abstract: Cerebral cavernous malformations (CCM) are developmental venous dysplasias which present as abnormally dilated blood vessels occurring mainly in the brain. Alterations in vascular biology originate from somatic mutations in genes regulating angiogenesis and endothelial-to-mesenchymal transition. Vascular lesions may occur at any time and develop silently, remaining asymptomatic for years. However, symptomatic disease is often debilitating, and patients are prone to develop drug-resistant epilepsy and hemorrhag… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 208 publications
0
2
0
Order By: Relevance
“…ROCK inhibitors have emerged as interesting candidates for treating neurodegenerative diseases [ 55 , 56 ]. A series of N -sulfonylhydrazone derivatives were designed as Rho-associated kinase (ROCK) inhibitors [ 57 ] through molecular hybridization between the approved drug fasudil ( 67 ), a ROCK inhibitor [ 58 ], and 66 , a previously reported inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ) [ 59 ] ( Figure 18 ).…”
Section: The Methylation Effect In Pharmacodynamic Optimizationmentioning
confidence: 99%
See 1 more Smart Citation
“…ROCK inhibitors have emerged as interesting candidates for treating neurodegenerative diseases [ 55 , 56 ]. A series of N -sulfonylhydrazone derivatives were designed as Rho-associated kinase (ROCK) inhibitors [ 57 ] through molecular hybridization between the approved drug fasudil ( 67 ), a ROCK inhibitor [ 58 ], and 66 , a previously reported inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ) [ 59 ] ( Figure 18 ).…”
Section: The Methylation Effect In Pharmacodynamic Optimizationmentioning
confidence: 99%
“…Barbosa and colleagues [46] described a series of combretastatin A-4 analogs based on the N-acylhydrazone (NAH) LASSBio-1586 (54) with cytotoxic and antimitotic activity (Figure 14). Homologation [9] studies on the amide nitrogen led to the benzyl homolog of LASSBio-1586 (54), LASSBio-2070 (56), which showed microtubule-stabilizing behavior, while the methylated homolog, LASSBio-1735 (55), had microtubule-destabilizing behavior. In addition, none of the compounds had better cytotoxic activity when compared to the N-methylated compound LASSBio-1735 (55) [46].…”
Section: Putative Dual Inhibitor Of Tubulin and Egfr By Phenotypic Ap...mentioning
confidence: 99%